The New England journal of medicine 2018 10 01() doi 10.1056/NEJMe1812434 AbstractRead More
Biomedical journal 38(1) 5-8 doi 10.4103/2319-4170.151150 Abstract The first Tang Prize for Biopharmaceutical Science has been awarded to Prof. James P. Allison and Prof. Tasuku Honjo for their contributions leading to an...Read More
The New England journal of medicine 2018 09 25() doi 10.1056/NEJMoa1809697 Abstract BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with...Read More
EBioMedicine 2018 09 29() pii 10.1016/j.ebiom.2018.09.015 Abstract BACKGROUND Senescence is a tumor suppressor mechanism activated in stressed cells to prevent replication of damaged DNA. Senescent cells have been demonstrated...Read More
The New England journal of medicine 2018 09 25() doi 10.1056/NEJMoa1810171 Abstract BACKGROUND Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive...Read More
The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function.
Cell reports 25(1) 80-94 pii 10.1016/j.celrep.2018.09.012 Abstract We examined hematopoietic protein kinase 1 (HPK1), whose reliance on scaffold versus kinase functions for negative immune cell regulation is poorly understood...Read More
Cells 2018 10 017(10) pii 10.3390/cells7100155 Abstract Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably...Read More
Positive and negative regulation of cellular immune responses in physiologic conditions and diseases.
Clinical & developmental immunology 2012 03 262012() 485781 doi 10.1155/2012/485781 Abstract The immune system has evolved to allow robust responses against pathogens while avoiding autoimmunity. This is notably enabled by...Read More
Angewandte Chemie (International ed. in English) 2017 11 2857(16) 4143-4148 doi 10.1002/anie.201708408 Abstract Tailor-made: Discussed herein is the ability to adapt biology’s mechanisms for innovation and optimization to...Read More
- CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops.
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
- Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
- Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.